Vicadrostat (Osilodrostat) for Cushing's Syndrome

Mechanism and Efficacy

Vicadrostat blocks cortisol production by inhibiting the enzyme 11β-hydroxylase in the adrenal glands, making it highly effective for rapidly lowering dangerously high cortisol levels in patients with Cushing's syndrome 1, 2
The American College of Endocrinology recommends vicadrostat as a treatment option for Cushing's syndrome due to its ability to normalize cortisol levels in 77% of patients within 12 weeks 1, 3
Vicadrostat achieves higher rates of cortisol normalization compared to metyrapone or ketoconazole, with a more favorable dosing schedule 1, 2

By 48 weeks of treatment, patients experience significant weight loss and reduction in body fat 2
Patients also experience lower blood sugar control and decreased HbA1c levels 2
Vicadrostat reduces total and LDL cholesterol 3
The medication improves quality of life scores and reduces depression symptoms 2

The Endocrine Society notes that hypocortisolism-related effects, such as fatigue and weakness, occur in approximately 27-50% of patients, mostly during the initial dose-adjustment period 2
Anemia occurs in 8-11% of patients 3
Regular cortisol level checks, electrolyte monitoring, and ECG monitoring for QT prolongation are necessary 2
Blood pressure checks are also recommended 2